Picard Medical released a pre-recorded annual stockholder presentation highlighting an 85% year-over-year revenue increase and progress on its Emperor next-generation total artificial heart.
Key Highlights:
- Announced availability of pre-recorded presentation ahead of the July 17, 2026 virtual Annual Meeting to review business and proposals.
- Reported an 85% year-over-year revenue increase and improved gross margin to 28% from year-end 2025, driven by 116% U.S. revenue growth.
- Outlined manufacturing optimization efforts to strengthen quality control, supply chain resilience, and reduce production costs.
- Updated on Emperor platform: electromechanical drive aiming to remove external pneumatic driver; initial config keeps external controller and battery.
- Provided development timeline for Emperor: pursuing Breakthrough Device designation, preclinical work, IDE planned in 2028, potential clinical studies in 2029.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.